Clinical Trials in Massachusetts

Showing 2421-2440 of 8,511 trials

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

NCT03361852

This research study is studying a novel type of FL vaccine as a possible treatment for follicular lymphoma (FL). The agents involved in this study are: * Rituximab * Personalized NeoAntigen vaccine * Poly-ICLC * Pembrolizumab

Follicular Lymphoma

Dana-Farber Cancer Institute20 participantsStarted Mar 2022

Boston, Massachusetts, United States

COMPLETEDNA26 miles

Ureteral Stent Placement After Ureteroscopy for Renal Stones: A Randomized Controlled Trial

NCT03855787

The rationale for this study is to determine if there is a difference in complications among patients undergoing ureteroscopy for renal stones who receive a stent compared to not receiving a stent postoperatively.

Kidney Calculi

Vanderbilt University Medical Center103 participantsStarted Nov 2019

Los Angeles, California, United States • Sacramento, California, United States • San Diego, California, United States +4 more locations

Active Not RecruitingPhase 126 miles

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

NCT02632708

The purpose of this Phase I, multicenter, clinical trial is to evaluate the safety of AG-120 and AG-221 when given in combination with standard AML induction and consolidation therapy. The study plans to evaluate up to 2 dose levels of AG-120 in participants with an isocitrate dehydrogenase protein 1 (IDH1) mutation and up to 2 dose levels of AG-221 in participants with an isocitrate dehydrogenase protein 2 (IDH2) mutation. AG-120 or AG-221 will be administered with 2 types of AML induction therapies (cytarabine with either daunorubicin or idarubicin) and 2 types of AML consolidation therapies (mitoxantrone with etoposide \[ME\] or cytarabine). After consolidation therapy, participants may continue on to maintenance therapy and receive daily treatment with single-agent AG-120 or AG-221 until relapse, development of an unacceptable toxicity, or hematopoietic stem cell transplant (HSCT). The study will end when all participants have discontinued study treatment.

Newly Diagnosed Acute Myeloid Leukemia (AML)Untreated AMLAML Arising From Myelodysplastic Syndrome (MDS)+2 more

Institut de Recherches Internationales Servier153 participantsStarted Dec 2015

Duarte, California, United States • Los Angeles, California, United States • Aurora, Colorado, United States +14 more locations

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

Ureteral Stent Placement After Ureteroscopy for Renal Stones: A Randomized Controlled Trial

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Find Trials by Condition in Massachusetts

Amivantamab in Adenoid Cystic Carcinoma

Collagen Matrix + rhPDGF-BB vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences

Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence

A Phase 3 Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

Conduction System Pacing Optimized Therapy

Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes

Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief

BAsel Syncope EvaLuation (BASEL IX) Study

A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors